Focused On-demand Library for Oligophrenin-1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

O60890

UPID:

OPHN1_HUMAN

Alternative names:

Alternative UPACC:

O60890; B9EIP8; Q5JQ81; Q6PCC1; Q8WX47

Background:

Oligophrenin-1, encoded by the gene with accession number O60890, plays a pivotal role in neuronal activity. It stimulates GTP hydrolysis of Rho family members, influencing dendritic spine growth and synaptic function stabilization. It is essential for AMPA receptor stabilization at postsynaptic sites, synaptic vesicle endocytosis at presynaptic terminals, and protecting NR1D1 from degradation.

Therapeutic significance:

Oligophrenin-1's malfunction is linked to Intellectual developmental disorder, X-linked, syndromic, Billuart type, characterized by intellectual disability, cerebellar hypoplasia, and facial dysmorphism. Understanding its role could lead to novel therapeutic strategies for this disorder.